Monopar Therapeutics (NASDAQ:MNPR) and NorthStar Medical Radioisotopes today announced significant amendments and expansions to their existing collaboration.

As part of the updated agreement, NorthStar will supply Monopar with the therapeutic radioisotope actinium-225 (Ac-225) under a long-term, non-exclusive master supply agreement.

This revision extends NorthStar’s robust investment in Ac-225 manufacturing capabilities and leverages Monopar’s promising preclinical therapeutic outcomes with Ac-225 in its flagship MNPR-101 radiopharma program.

The updated collaboration agreement also refines the economic terms and clarifies rights related to jointly developed intellectual property for Monopar’s MNPR-101 radiopharmaceutical applications.

Monopar has secured these rights from NorthStar, gaining full ownership and title to its lead MNPR-101 radiopharmaceutical platform, which includes a wide range of jointly developed intellectual property.

Additionally, both companies will share ownership of a filed patent application for the use of PCTA as a linker with Ac-225.

This new linker has demonstrated superior binding and yield with Ac-225 compared to DOTA, the current industry-leading linker, marking a significant advancement in the field of radiopharmaceuticals.